Rivipansel
- Generic Name
- Rivipansel
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C58H74N6O31S3
- CAS Number
- 927881-99-0
- Unique Ingredient Identifier
- 4B115V09LB
- Background
Rivipansel has been used in trials studying the other, basic science, and treatment of Pain Crisis, Renal impairment, Anemia, Sickle Cell, Sickle Cell Disease, and Sickle Cell Disorders, among others.
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.
- First Posted Date
- 2016-12-20
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT02998099
- Locations
- πΊπΈ
Orlando Clinical Research Center, Orlando, Florida, United States
A Study to Evaluate the Effect of IV Doses of Rivipansel in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function
- Conditions
- Interventions
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2020-07-09
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 16
- Registration Number
- NCT02871570
- Locations
- πΊπΈ
Orlando Clincial Research Center, Orlando, Florida, United States
A Study to Evaluate the Effect of IV Doses of Rivipansel on Subjects With Renal Impairment and in Healthy Subjects
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT02813798
- Locations
- πΊπΈ
Anaheim Clinical Trials, LLC, Anaheim, California, United States
πΊπΈAvail Clinical Research, LLC, DeLand, Florida, United States
πΊπΈOrlando Clinical Research Center, Orlando, Florida, United States
Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2015-05-04
- Last Posted Date
- 2021-02-10
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 154
- Registration Number
- NCT02433158
- Locations
- πΊπΈ
University of Maryland Medical System, Baltimore, Maryland, United States
πΊπΈThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
πΊπΈJohns Hopkins Medicine, Baltimore, Maryland, United States
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Rivipansel With rHuPH20 in Healthy Subjects
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 27
- Registration Number
- NCT02217917
- Locations
- π§πͺ
Pfizer Clinical Research Unit, Brussels, Belgium
Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2020-06-22
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 345
- Registration Number
- NCT02187003
- Locations
- πΊπΈ
Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
πΊπΈThe Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
πΊπΈChildren's Healthcare of Atlanta Aflac Cancer and Blood Disorders Center, Atlanta, Georgia, United States
A Study to Evaluate the Effect of IV Doses of GMI-1070 on Qtc Intervals in Healthy African-American Adult Subjects
- First Posted Date
- 2013-09-13
- Last Posted Date
- 2020-06-18
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 48
- Registration Number
- NCT01941511
- Locations
- πΊπΈ
Pfizer Investigational Site, San Antonio, Texas, United States
Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis
- Conditions
- Interventions
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2020-05-13
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 81
- Registration Number
- NCT01119833
- Locations
- πΊπΈ
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States
πΊπΈThe Johns Hopkins School of Medicine, Baltimore, Maryland, United States
πΊπΈUniversity of California, Davis Medical Center, Sacramento, California, United States
Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease
- First Posted Date
- 2009-06-02
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- GlycoMimetics Incorporated
- Target Recruit Count
- 15
- Registration Number
- NCT00911495
- Locations
- πΊπΈ
Duke Comprehensive Sickle Cell Center, Durham, North Carolina, United States
πΊπΈChildren's Hospital & Research Center Oakland, Oakland, California, United States
πΊπΈUniversity of California at Davis, CCRC, Sacramento, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.